Want to see HK:2617 full AI Analyst Report?
2617 Stock Chart & Stats
HK$69.20
--
Market closed
HK$69.20
--
Day’s Range― - ―
52-Week RangeHK$9.01 - HK$679.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.21M
Market Cap
HK$3.51B
Enterprise ValueHK$9.24B
Total Cash (Recent Filing)HK$489.14M
Total Debt (Recent Filing)HK$1.65M
Price to Earnings (P/E)―
Beta3.38
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding312,687,680
10 Day Avg. Volume2,613,813
30 Day Avg. Volume4,211,017
Financial Highlights & Ratios
PEG Ratio-13.39
Price to Book (P/B)96.58
Price to Sales (P/S)0.00
P/FCF Ratio-158.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative FinancingVery low debt levels materially reduce near-term refinancing and interest-rate risk, giving the company financial flexibility while it invests in R&D. For a pre-revenue biopharma, low leverage lengthens runway and lowers the probability of solvency stress during lengthy clinical development.
Balance Sheet Strengthened Vs 2020The firm’s capital structure has meaningfully improved since 2020, when equity was negative and leverage high. That structural repair suggests management and financing actions have restored a stronger starting point for future funding rounds and reduces the baseline insolvency risk compared with earlier years.
Improving Free Cash Flow TrendAlthough still negative, improving free cash flow across consecutive years indicates the company is making progress on cash consumption efficiency or milestone-driven receipts. A sustained improvement trajectory would reduce external funding needs and improves the durability of the business model through development cycles.
Bears Say
Pre-revenue With Large Recurring LossesThe company reported no revenue in the last two years while incurring very large net losses, reflecting a classic pre-commercial biotech profile. Persistent lack of operating revenue means the firm has limited internal capacity to fund development, heightening dependency on external capital and increasing execution risk.
Material Negative Operating And Free Cash FlowSubstantial negative operating and free cash flow indicate ongoing cash burn tied to operations and R&D. If this pace persists, the company will require additional financing, which can dilute shareholders or be costly. Large burn rates also constrain strategic optionality and make long-term planning dependent on capital markets.
Erosion Of Equity And AssetsDeclining equity and asset levels from recent years reflect cumulative losses and cash depletion. This gradual erosion reduces the firm’s financial cushion, increases vulnerability to shocks, and can force financing on adverse terms if development timelines or trial outcomes lengthen or disappoint.
TransThera Sciences (Nanjing). Inc. News
2617 FAQ
What was TransThera Sciences (Nanjing). Inc.’s price range in the past 12 months?
TransThera Sciences (Nanjing). Inc. lowest stock price was HK$9.01 and its highest was HK$679.50 in the past 12 months.
What is TransThera Sciences (Nanjing). Inc.’s market cap?
TransThera Sciences (Nanjing). Inc.’s market cap is HK$3.51B.
When is TransThera Sciences (Nanjing). Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TransThera Sciences (Nanjing). Inc.’s earnings last quarter?
Currently, no data Available
Is TransThera Sciences (Nanjing). Inc. overvalued?
According to Wall Street analysts TransThera Sciences (Nanjing). Inc.’s price is currently Overvalued.
Does TransThera Sciences (Nanjing). Inc. pay dividends?
TransThera Sciences (Nanjing). Inc. does not currently pay dividends.
What is TransThera Sciences (Nanjing). Inc.’s EPS estimate?
TransThera Sciences (Nanjing). Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TransThera Sciences (Nanjing). Inc. have?
TransThera Sciences (Nanjing). Inc. has 312,687,680 shares outstanding.
What happened to TransThera Sciences (Nanjing). Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TransThera Sciences (Nanjing). Inc.?
Currently, no hedge funds are holding shares in HK:2617
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransThera Sciences (Nanjing). Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.25%
Trailing 12-Months
Company Description
TransThera Sciences (Nanjing). Inc.
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―